GeneThera Financials
| GTHR Stock | USD 0.0001 0.00 0.00% |
GeneThera |
Understanding current and past GeneThera Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of GeneThera's financial statements are interrelated, with each one affecting the others. For example, an increase in GeneThera's assets may result in an increase in income on the income statement.
GeneThera Stock Summary
GeneThera competes with Rigel Pharmaceuticals, Geron, Verastem, Immutep, and Elevation Oncology. GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 3051 West 105th |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.genethera.net |
| Phone | 720 587 5100 |
| Currency | USD - US Dollar |
GeneThera Key Financial Ratios
There are many critical financial ratios that GeneThera's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that GeneThera reports annually and quarterly.| Return On Asset | -95.38 | |||
| Beta | 0.89 |
GeneThera Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining GeneThera's current stock value. Our valuation model uses many indicators to compare GeneThera value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GeneThera competition to find correlations between indicators driving GeneThera's intrinsic value. More Info.GeneThera is one of the top stocks in return on asset category among its peers. It also is rated as one of the top companies in current valuation category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GeneThera's earnings, one of the primary drivers of an investment's value.GeneThera Systematic Risk
GeneThera's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. GeneThera volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on GeneThera correlated with the market. If Beta is less than 0 GeneThera generally moves in the opposite direction as compared to the market. If GeneThera Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GeneThera is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GeneThera is generally in the same direction as the market. If Beta > 1 GeneThera moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.